American College Of Rheumatology Meeting 2024. If you haven’t registered for acr convergence 2024, register today to participate in this year’s premier. This website contains abstracts from upcoming and previous acr meetings.
New phase 2b study results for zasocitinib, an investigational oral selective tyrosine kinase 2 (tyk2) inhibitor, will be presented at the american college of rheumatology (acr). Acr convergence, the american college of rheumatology’s annual meeting, brings together rheumatology professionals from around the world to learn, network, and grow.